May 29, 2025 --

Today, Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, announced that it will showcase its latest research highlights through more than 155 accepted abstracts and presentations at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, held in Chicago from May 30-June 3, 2025. Over 75 investigators from more than 20 research sites in SCRI’s network are first authors and co-authors on the clinical trial updates featured at the Annual Meeting, including findings from 55 early-phase clinical trials.

"We are excited to join our colleagues from around the world at ASCO’s Annual Meeting to share the latest developments in research that are advancing therapies for patients," says Howard A. “Skip” Burris, III, MD, President, SCRI. "From developments in novel agents to findings in a variety of cancers, the research presented by SCRI leaders not only highlights how our work is accelerating drug development, but also our dedication to ensuring people facing cancer have access to innovative treatments closer to home."

For a comprehensive list of SCRI abstracts and presentations, visit SCRI’s ASCO Site. To learn more about our research experts, visit our Leadership Page.

Noteworthy Presentations

Blood Cancer

Breast Cancer

Cancer Detection

Lung Cancer

Solid Tumors

In addition to the above, Dr. Erika Hamilton and Dr. David Spigel will serve in two prestigious leadership roles, as 2025 ASCO Annual Meeting Scientific Program Committee Chair and Cancer Communications Committee Chair, respectively.

In addition to scientific presentations, SCRI leadership will participate in and lead ASCO sessions, including:

Additional Poster Presentations with SCRI First Authors

Saturday, May 31

Monday, June 2

  • “ZL-1310, a DLL3 ADC, in Patients with Extensive Stage Small Cell Lung Cancer: Ph1 Trial Update,” Manish Patel, MD, SCRI at Florica Cancer Specialists & Research Institute, 1:30 p.m. – 4:30 p.m. CDT, Hall A.
  • “First-in-Human Phase 1 Study of CUSP06, a Cadherin-6-Directed Antibody-Drug Conjugate, in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors,” Dr. Manish Patel, 1:30 p.m. - 4:30 p.m. CDT, Hall A.
  • “First-in-Human Study of BG-C9074, a B7-H4-Targeting ADC in Patients with Advanced Solid Tumors: Preliminary Results of the Dose-Escalation Phase,” Cesar Perez, MD, SCRI at Florida Cancer Specialists & Research Institute, 1:30 p.m. – 4:30 p.m. CDT, Hall A.
  • “Efficacy and Safety of Pralsetinib in RET Fusion-Positive Solid Tumors: Final Data from the ARROW Trial,” Vivek Subbiah, MD, 1:30 p.m. – 4:30 p.m. CDT, Hall A.
  • “Efficacy and Safety Results of a Multi-Center Phase I Study of Utidelone Capsule, a Novel Oral Microtubule Inhibitor, in Advanced Solid Tumor Patients,” Dr. Judy Wang, 1:30 p.m. – 4:30 p.m. CDT, Hall A.

About Sarah Cannon Research Institute

Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI’s research network brings together more than 1,300 physicians who are enrolling patients into clinical trials at over 200 locations in more than 20 states across the U.S. Visit SCRI.com to learn more.